Oncotarget

Reviews:

Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data

Xu Sun, Ganlin Zhang, Jiayun Nian, Mingwei Yu, Shijian Chen, Yi Zhang, Guowang Yang, Lin Yang, Peiyu Cheng, Chen Yan, Yunfei Ma, Hui Meng, Xiaomin Wang _ and Jin-Ping Li

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43521-43535. https://doi.org/10.18632/oncotarget.16575

Metrics: PDF 1910 views  |   HTML 3005 views  |   ?  


Abstract

Xu Sun1, Ganlin Zhang1, Jiayun Nian1,2, Mingwei Yu1, Shijian Chen3, Yi Zhang1, Guowang Yang1, Lin Yang1, Peiyu Cheng1, Chen Yan1,2, Yunfei Ma1, Hui Meng1,2, Xiaomin Wang1 and Jin-Ping Li1,4

1 Department of Oncology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China

2 School of Graduates, Beijing University of Chinese Medicine, Beijing, China

3 Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China

4 Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

Correspondence to:

Xiaomin Wang, email:

Keywords: heparanase, breast cancer, prognosis

Received: September 09, 2016 Accepted: March 10, 2017 Published: March 25, 2017

Abstract

Heparanase promotes tumorigenesis, angiogenesis, and metastasis. Here, we conducted a study based on systematic review and the Cancer Genome Atlas (TCGA) data that examined heparanase expression in clinical samples to determine its prognostic value. According to the meta-analysis and TCGA data, we found that heparanase expression was up-regulated in most breast cancer specimens, and elevated heparanase expression was associated with increased lymph node metastasis, larger tumor size, higher histological grade, and poor survival. These results suggest that targeting heparanase might improve treatments for breast cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16575